Advertisement

Ads Placeholder
Loading...

Bristol-Myers Squibb Company Ce

CELG-RI•NYSE
Healthcare
Drug Manufacturers - General
$0.12
$0.03(34.76%)
U.S. Market opens in 3h 54m

Bristol-Myers Squibb Company Ce (CELG-RI) Stock Overview

Explore Bristol-Myers Squibb Company Ce’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap243.2M
P/E Ratio0.03
EPS (TTM)N/A
ROE0.39%
Fundamental Analysis

AI Price Forecasts

1 Month$0.13
3 Months$0.09
1 Year Target$0.09

CELG-RI Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Bristol-Myers Squibb Company Ce (CELG-RI) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 51.12, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.09.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 0.03 and a market capitalization of 243.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
34.76%
5-Day Change
27.02%
1-Month Change
-20.40%
3-Month Change
49.87%
6-Month Change
213.39%
Year-to-Date (YTD) Change
49.87%
1-Year Change
241.14%
3-Year Change
-11.56%
5-Year Change
-22.92%
All-Time (Max) Change
-22.92%

Contact Information

http://www.bms.com
Princeton, DE

Company Facts

34,100 Employees
CountryUS
Actively Trading

Frequently Asked Questions